A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD)

Study Summary

RGX-202-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-202 in participants who have received RGX-202 (an investigative gene therapy designed to deliver a transgene for novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain) in a separate parent study.

Interventions

Study Locations

Facility	City	State	Country
Arkansas Children's Hospital	Little Rock	Arkansas	United States
Stanford School of Medicine /Division of Neuromuscular Medicine	Palo Alto	California	United States
Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	United States
The University of Texas Southwestern Medical Center	Dallas	Texas	United States
Virginia Commonwealth University	Richmond	Virginia	United States

Official Trial Information

View on ClinicalTrials.gov